AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd's Syndicate 1902, for its Phase III clinical trial ...
EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA AB Science SA (Euronext - FR0010557264 - AB) announces ...
Good morning, and good afternoon for the participant to our web conference organized by AB Science. About an update of the clinical development of our asset called AB8939. My name is Alain Moussy, I'm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results